Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Yi LiuLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0009-0003-2212-1364
Zhihui FengLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0009-0004-0925-2391
Biao ZhangLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0009-0004-2241-9440
Xueli YangLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0009-0004-6836-0923
Fei YangLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0009-0003-8943-5405
Guiya LuLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0009-0003-6970-7004
Chunhong LiLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0000-0003-2943-0306
Chune MoLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0000-0002-0449-770X
Minglin OuLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0000-0001-7583-5190
Xianliang HouLaboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China, glmc.edu.cn.ORCID https://orcid.org/0000-0003-1271-6826
Funding
Bagui Youth Top-notch Personnel Program of GuangxiBasic and Applied Basic Research Foundation of Guangdong Province 2025A1515012661Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center GWJJMB202510025042Guangdong Province Medical Science and Technology Research Foundation B2025207Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation 2021KF001Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation 2023KF006Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation 3030302213Guangxi Medical and Health Appropriate Technology Development and Promotion Project S2024075Guilin Science Research and Technology Development Project 20220139-13-2Guilin Science Research and Technology Development Project 20230135-4-2Innovation Training Program for College Students S202510601079Innovation Training Program for College Students X202510601230Innovation Training Program for College Students X202510601258National Natural Science Foundation of China 82101877National Natural Science Foundation of China 82460324Natural Science Foundation of Guangxi Zhuang Autonomous Region 2024GXNSFAA010096Shenzhen Hospital (Longgang) of Beijing University of Chinese Medicine 2023-BUCMSZYLRC42Shenzhen Science and Technology Program JCYJ20230807150913027Shenzhen Science and Technology Program JCYJ20240813165111016
6 · The paper itself
Abstract
Autoimmune diseases are chronic disorders with complex pathogenesis. Immune homeostasis disruption is closely associated with disease initiation and progression. Despite extensive research, the precise mechanisms underlying these diseases remain elusive. Conventional therapeutic approaches for autoimmune diseases primarily involve the administration of immunosuppressants, glucocorticoids, and monoclonal antibodies, each of which presents certain limitations. The emergence of RNA interference (RNAi) therapeutics has introduced a novel avenue for addressing these conditions. The development of an optimally engineered vector for RNAi drugs is anticipated to significantly enhance their clinical applicability. Nanomaterials, as promising drug carriers, offer robust support for RNAi therapeutics. This review summarizes recent advances and applications of nanodelivery systems for small interfering RNA (siRNA) therapeutics in autoimmune disease treatment. It also analyzes the challenges and future prospects of nanomaterial application in this field.
Indexed as
Autoimmune DiseasesDrug Delivery SystemsRNAi TherapeuticsRNA, Small InterferingAnimalsDrug CarriersHumansNanoparticlesNanostructuresRNA InterferenceDrug CarriersRNA, Small Interferingautoimmune diseasesnanomaterialsrheumatoid arthritisRNAisiRNA
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
siRNA-Based Nanodrug Delivery Systems in the Treatment of Autoimmune Diseases. · full record | OpenQuestion